Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, single-arm, open-label study to evaluate the safety, PK, and tolerability of a repeated (3 times weekly) dose of difelikefalin administered as IV bolus injections to adult Chinese HD subjects. Treatment period is one week and there is a safety follow-up period of 1 week.


Clinical Trial Description

This is a Phase 1, single-arm, open-label study to evaluate the safety, PK, and tolerability of a repeated (3 times weekly) dose of difelikefalin administered as IV bolus injections to adult Chinese HD subjects. Total study duration for a single subject is up to 5 weeks including a screening period of up to 3 weeks, a treatment period of 1 week, and a safety follow-up period of 1 week. The duration of PK sampling is 12 days. The primary objective of the study is to evaluate the PK profile of a repeated (3 times weekly) dose of difelikefalin in Chinese HD subjects over a 1-week treatment period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05885763
Study type Interventional
Source Vifor Fresenius Medical Care Renal Pharma
Contact
Status Completed
Phase Phase 1
Start date June 26, 2023
Completion date October 9, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02860312 - Long Term Physical Activity for Hemodialysis Patients N/A